
Enduro
Employs synthetic biology to optimize yield and maintain high performance in large-scale fermentation processes.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | €12.0m | Series A | |
Total Funding | 000k |
DKK | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Developer of a genetic plugin technology designed to improve the efficiency and scalability of large-scale fermentations. The company's technology addresses a key challenge in industrial bioproduction: maintaining high yields and consistent performance at scale while avoiding reliance on antibiotic resistance markers. By enriching spontaneous high producers within the fermentation population, the technology ensures that even under stressful industrial conditions, production strains maintain elevated titers and stable output.
The approach is specifically engineered to overcome common sources of strain instability that often limit bioproduction of complex or inhibitory molecules. Strain instability can result in inconsistent yields, process failures, or the need for costly interventions. By stabilizing production traits at the genetic level, this solution enables manufacturers to produce more complex or traditionally difficult products efficiently and reliably.
Free from antibiotic resistance genes, the technology aligns with regulatory and environmental demands for safer, cleaner bioproduction methods. This design reduces biosafety risks and supports a shift away from antibiotic-dependent selection systems, addressing industry goals around sustainability and responsible manufacturing.
The genetic plugin is adaptable to a wide range of host strains and production targets, offering flexibility to manufacturers seeking to optimize existing production lines without the need to develop entirely new processes. This makes the technology especially valuable for companies looking to scale green bioproduction as a competitive alternative to fossil-based manufacturing.
Through partnerships with producers across pharmaceuticals, biotechnology, and industrial biomanufacturing, the company provides a tool for maximizing the performance of all cells cultivated from production strains. By delivering higher yields, improved stability, and lower process risk, the technology supports the economic viability of sustainable manufacturing at scale.
Ultimately, the company's mission is to advance the competitiveness of green bioproduction, making biologically based manufacturing processes a practical and attractive alternative to traditional chemical synthesis. By equipping producers with tools to reliably scale production of complex molecules, it contributes to broader goals of decarbonization, sustainability, and innovation in industrial biotechnology.
Keywords: Pharmaceuticals and Biotechnology, Bioproduction Facility, Bioproduction Technology, Biotechnology Research, Genetic Fermentation, Genetic Lines, Genetic Plugin, Production Strain, Sustainable Manufacturing, Industrial Biotechnology